Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) FCF Yield % : -5.58 (As of May. 20, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Corbus Pharmaceuticals Holdings's Trailing 12-Month Free Cash Flow is $-28.95 Mil, and Market Cap is $518.84 Mil. Therefore, Corbus Pharmaceuticals Holdings's FCF Yield % for today is -5.58%.

The historical rank and industry rank for Corbus Pharmaceuticals Holdings's FCF Yield % or its related term are showing as below:

CRBP' s FCF Yield % Range Over the Past 10 Years
Min: -355.26 Med: -11.91 Max: -2.18
Current: -5.58

During the past 11 years, the highest FCF Yield % of Corbus Pharmaceuticals Holdings was -2.18%. The lowest was -355.26%. And the median was -11.91%.

CRBP's FCF Yield % is ranked better than
67.12% of 1557 companies
in the Biotechnology industry
Industry Median: -14.1 vs CRBP: -5.58

Corbus Pharmaceuticals Holdings's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

Corbus Pharmaceuticals Holdings FCF Yield % Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings FCF Yield % Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-13.72

-81.07

-62.56

-271.60

-135.11

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-197.30	-89.98	-96.27	-89.96	-7.73

Competitive Comparison of Corbus Pharmaceuticals Holdings's FCF Yield %

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's FCF Yield % falls into.

Corbus Pharmaceuticals Holdings FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Corbus Pharmaceuticals Holdings's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-36.1	/	26.7190272
	=	-135.11%

Corbus Pharmaceuticals Holdings's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-7.967	*	4	/	412.302528
	=	-7.73%

Corbus Pharmaceuticals Holdings FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Corbus Pharmaceuticals Holdings FCF Yield % Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

3371:Germany

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Executives

Yong Ben	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Yuval Cohen	director, officer: Chief Executive Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian	officer: Chief Commercial Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran	officer: Chief Financial Officer	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Rachael Louise Brake	officer: Chief Scientific Officer	21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White	officer: Chief Medical Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia	officer: Chief Operating Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman	director	15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alan F Holmer	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062